Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. has enhanced its financial outlook through the expansion of its Cortrophin sales force, leading to increased revenue estimates and potential multiple expansion. This strategic move is supported by positive trends in the company's weekly TRx tracker, indicating that Cortrophin is exceeding prior performance expectations. Furthermore, ANI's data-driven approach has improved its capability to address payer inquiries, facilitating a smoother approval process for patient prescriptions and reinforcing its market position.

Bears say

ANI Pharmaceuticals Inc faces significant financial challenges that contribute to a negative outlook for its stock. The company carries a substantial debt load exceeding $600 million, which adds financial strain and increases vulnerability to external market pressures. Additionally, the risks related to pricing, reimbursement, competitive threats, and potential manufacturing issues further complicate the company's commercial execution and overall stability in a competitive pharmaceutical landscape.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.